GPA Flashcards

(25 cards)

1
Q

What is Granulomatosis with Polyangiitis (GPA)?

A

GPA is a necrotizing granulomatous vasculitis of small to medium vessels, associated with PR3-ANCA (c-ANCA), affecting the upper airways, lungs, and kidneys.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Which antibody is most commonly associated with GPA?

A

c-ANCA (PR3-ANCA) – positive in ~90% of generalized cases.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are the hallmark pathological features of GPA?

A

Necrotizing granulomatous inflammation, vasculitis, and tissue necrosis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What is the classic triad in GPA?

A
  1. Upper respiratory tract involvement
  2. Lower respiratory tract involvement
  3. Glomerulonephritis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What upper airway features suggest GPA?

A

• Persistent sinusitis
• Nasal crusting or epistaxis
• Saddle-nose deformity (from septal perforation)
• Otitis media

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What causes saddle-nose deformity in GPA?

A

Cartilage destruction due to granulomatous inflammation of the nasal septum.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What are typical lung manifestations in GPA?

A

• Cough, hemoptysis, dyspnea
• Cavitating pulmonary nodules or infiltrates
• Alveolar hemorrhage (life-threatening)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

How does GPA differ from EGPA in lung findings?

A

GPA shows fixed cavitating nodules; EGPA shows transient infiltrates and eosinophilia.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What type of glomerulonephritis is seen in GPA?

A

Rapidly progressive glomerulonephritis (RPGN) with crescent formation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What urine findings suggest renal involvement in GPA?

A

Hematuria, proteinuria, red cell casts.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What skin findings may be seen in GPA?

A

Palpable purpura, ulcers, livedo reticularis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What neurological complications may occur in GPA?

A

Mononeuritis multiplex, peripheral neuropathy.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Name 2 rare cardiac complications in GPA.

A

Pericarditis, coronary arteritis (less common than in EGPA).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What is the most specific diagnostic test for GPA?

A

Positive PR3-ANCA (c-ANCA); tissue biopsy is definitive.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What are typical biopsy findings in GPA?

A

Necrotizing granulomatous inflammation and vasculitis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What does a chest X-ray show in GPA?

A

Multiple bilateral cavitating nodules or infiltrates.

17
Q

What confirms renal involvement in GPA?

A

Renal biopsy showing pauci-immune crescentic glomerulonephritis.

18
Q

What are key differentials of GPA?

A

• EGPA (with asthma/eosinophilia)
• Microscopic polyangiitis (no granulomas, more renal involvement)
• Tuberculosis (for cavitating lung nodules)
• Sarcoidosis (non-necrotizing granulomas)

19
Q

How is induction therapy initiated in GPA?

A

• High-dose corticosteroids (IV methylprednisolone)
• Plus cyclophosphamide or rituximab

20
Q

When is plasmapheresis considered in GPA?

A

In severe renal failure or alveolar hemorrhage (controversial, case-by-case).

21
Q

What agents are used for maintenance therapy?

A

Azathioprine, methotrexate, or mycophenolate.

22
Q

What biologic can be used for relapse or refractory GPA?

A

Rituximab (anti-CD20 monoclonal antibody).

23
Q

What is the relapse rate in GPA?

A

High – ~50% within 5 years after initial remission.

24
Q

What is the role of ANCA titres in monitoring GPA?

A

May correlate with disease activity but are not always reliable alone.

25
What is the overall prognosis with treatment?
5-year survival >80% with immunosuppressive therapy.